Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.
Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, You YF, Xiao J, Xiong Y, Wang W, Pang H, Guo JJ, Cai SB, Wang D, Li CR, Zhang M, Bu BT, Wang W.
Qin C, et al. Among authors: dong mh.
Signal Transduct Target Ther. 2023 Jan 4;8(1):5. doi: 10.1038/s41392-022-01278-3.
Signal Transduct Target Ther. 2023.
PMID: 36596762
Free PMC article.
Clinical Trial.